Compounders Question FDAs Rationale and Evidence Pointing to Safety Concerns On October 27, 2023, APC urged FDA via letter addressed to Gail Bormel, Director of the FDA's Office of Compounding Quality and Compliance, for transparency regarding the recent inclusion of substances into Category 2
10.1016/j.bioorg.2004.06.005 61 RabahiF.BrlS.SiroisJ.BeckersJ
These changes occurred before the increase in THDA levels, indicating that the loss of BDNF-TrkB signalling and upregulation of GSTO2 happens before the hyperdopaminergic state, as with the Trkb Penk -KO mice, supporting that GSTO2 increase is more likely a cause of neurodegeneration than a consequence of it
[PMID: 7330902] PubMed record related to this compound for laboratory literature review
While -3 PUFAs are considered to have beneficial effects 40 , consumption of PUFAs has also been linked with more severe ALD in humans and experimental animals 41